Streetbeat News

ORTX

Orchard Therapeutics plc

https://www.orchard-tx.com/

Employees

207

Industry

Research and Development in Biotechnology

orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world.

Open

16.65

Mkt cap

380M

Volume

372K

High

16.72

P/E Ratio

-4.07

52-wk high

16.72

Low

16.64

Div yield

N/A

52-wk low

4.24

Orchard Therapeutics has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy for reimbursed access to Libmeldy, a treatment for early-onset Metachromatic Leukodystrophy (MLD). This agreement will allow patients in the Beneluxa region to have access to this gene therapy, which is approved for treating this rare and often fatal disease.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 12:16 pm

Kyowa Kirin has successfully completed the acquisition of Orchard Therapeutics, making it a wholly-owned subsidiary as of January 24, 2024, through a Scheme of Arrangement under the UK Companies Act 2006.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 10:34 am

Orchard Therapeutics (NASDAQ:ORTX) has received approval from Swissmedic for Libmeldy, a gene therapy for early-onset metachromatic leukodystrophy (MLD).

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:02 pm

Orchard Therapeutics announced that OTL-203, its investigational gene therapy for the treatment of the Hurler subtype of Mucopolysaccharidosis Type I, has received FDA Fast Track Designation. This designation could expedite the development and review process for OTL-203, potentially bringing it to market more quickly.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 12:04 pm

The US FDA has decided not to schedule an advisory committee meeting for Orchard Therapeutics' Biologics License Application for OTL-200, intended to treat Metachromatic Leukodystrophy, according to a recent SEC filing.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 1:13 pm

Orchard Therapeutics (NASDAQ:ORTX) reported Q3 earnings with an EPS of $-0.15, beating estimates by 80% compared to the expected $-0.75. However, revenue declined by $218 thousand from the same period last year. Following last quarter's earnings beat, the share price increased by 1.72% the next day.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 12:15 pm

U.S. stocks traded slightly lower with the Dow Jones index falling around 40 points. ConAgra Brands Inc (CAG) reported better-than-expected earnings for its first quarter. Orchard Therapeutics (ORTX) shares shot up 98% after agreeing to be acquired by Japan's Kyowa Kirin. Lamb Weston Holdings (LW) and SP Plus Corporation (SP) also saw significant increases in share prices. Cambium Networks Corporation (CMBM), Rivian Automotive (RIVN), and MaxCyte (MXCT) shares dropped significantly due to disappointing financial results and outlooks.

Portfolio Pulse from Lisa Levin

October 05, 2023 | 6:31 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Orchard Therapeutics, Histogen, Clene, Orgenesis, Omega Therapeutics, and Matinas BioPharma Hldgs saw their shares increase by 96.5%, 47.17%, 21.0%, 19.98%, 19.4%, and 15.85% respectively. On the other hand, MaxCyte, Longeveron, Viracta Therapeutics, Nanobiotix, SenesTech, and Renalytix saw their shares decline by 22.6%, 17.93%, 17.39%, 17.14%, 16.29%, and 16.11% respectively.

Portfolio Pulse from Benzinga Insights

October 05, 2023 | 5:31 pm

Several stocks experienced significant movement in Thursday's mid-day session. Orchard Therapeutics plc (ORTX) shares climbed 97.7% after agreeing to be acquired by Japan's Kyowa Kirin. SP Plus Corporation (SP) shares gained 47.5% after Metropolis Technologies announced it will acquire the company. Accolade Inc (ACCD) shares fell 9.9% after the company reported second-quarter results. Grupo Aeroportuario del Centro Norte (OMAB) shares dipped 39.6%.

Portfolio Pulse from Lisa Levin

October 05, 2023 | 5:23 pm

US stocks traded lower with the Dow Jones index falling over 100 points. Constellation Brands Inc (STZ) reported better-than-expected Q2 earnings and raised its FY24 EPS outlook. Orchard Therapeutics (ORTX) shares rose after agreeing to be acquired by Kyowa Kirin. Lamb Weston Holdings (LW) and SP Plus Corporation (SP) shares also rose after positive financial results and acquisition news respectively. Cambium Networks Corporation (CMBM), Rivian Automotive (RIVN), and MaxCyte (MXCT) shares fell due to disappointing financial forecasts.

Portfolio Pulse from Lisa Levin

October 05, 2023 | 4:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.